Wedbush Has Negative Outlook for BCRX FY2025 Earnings

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) - Stock analysts at Wedbush reduced their FY2025 earnings per share estimates for BioCryst Pharmaceuticals in a report issued on Wednesday, April 16th. Wedbush analyst L. Chico now expects that the biotechnology company will post earnings of $0.03 per share for the year, down from their prior estimate of $0.04. Wedbush has a "Outperform" rating and a $15.00 price objective on the stock. The consensus estimate for BioCryst Pharmaceuticals' current full-year earnings is ($0.36) per share. Wedbush also issued estimates for BioCryst Pharmaceuticals' Q4 2025 earnings at $0.10 EPS, Q1 2026 earnings at $0.02 EPS, Q2 2026 earnings at $0.07 EPS, Q4 2026 earnings at $0.14 EPS, FY2026 earnings at $0.32 EPS, FY2027 earnings at $0.66 EPS and FY2028 earnings at $0.84 EPS.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last announced its quarterly earnings data on Monday, February 24th. The biotechnology company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.06). The business had revenue of $131.50 million during the quarter, compared to analysts' expectations of $126.64 million. BioCryst Pharmaceuticals's quarterly revenue was up 40.8% on a year-over-year basis. During the same period in the previous year, the company earned $0.28 earnings per share.

Several other research firms also recently commented on BCRX. Needham & Company LLC reissued a "buy" rating and set a $15.00 target price on shares of BioCryst Pharmaceuticals in a research report on Thursday, April 10th. JMP Securities reiterated a "market outperform" rating and set a $18.00 target price on shares of BioCryst Pharmaceuticals in a research report on Friday, January 31st. Evercore ISI raised their price target on shares of BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the company an "outperform" rating in a report on Monday, January 13th. HC Wainwright reiterated a "buy" rating and issued a $30.00 target price on shares of BioCryst Pharmaceuticals in a research report on Tuesday, February 25th. Finally, Royal Bank of Canada reaffirmed an "outperform" rating and set a $11.00 target price on shares of BioCryst Pharmaceuticals in a report on Friday, April 11th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, BioCryst Pharmaceuticals has an average rating of "Moderate Buy" and an average price target of $15.57.

BioCryst Pharmaceuticals Stock Up 3.8 %

BioCryst Pharmaceuticals stock traded up $0.29 during mid-day trading on Thursday, hitting $7.82. 1,721,487 shares of the stock were exchanged, compared to its average volume of 2,798,530. BioCryst Pharmaceuticals has a 12 month low of $4.03 and a 12 month high of $9.50. The firm's fifty day simple moving average is $7.79 and its two-hundred day simple moving average is $7.74. The stock has a market capitalization of $1.63 billion, a price-to-earnings ratio of -12.79 and a beta of 1.75.

Institutional Trading of BioCryst Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Xponance Inc. raised its position in BioCryst Pharmaceuticals by 9.1% in the 4th quarter. Xponance Inc. now owns 14,896 shares of the biotechnology company's stock valued at $112,000 after purchasing an additional 1,242 shares during the last quarter. Sei Investments Co. grew its position in BioCryst Pharmaceuticals by 2.8% during the fourth quarter. Sei Investments Co. now owns 57,190 shares of the biotechnology company's stock valued at $430,000 after acquiring an additional 1,537 shares during the period. SG Americas Securities LLC lifted its stake in shares of BioCryst Pharmaceuticals by 5.2% during the first quarter. SG Americas Securities LLC now owns 43,496 shares of the biotechnology company's stock worth $326,000 after purchasing an additional 2,146 shares in the last quarter. SkyView Investment Advisors LLC increased its position in shares of BioCryst Pharmaceuticals by 30.0% during the third quarter. SkyView Investment Advisors LLC now owns 13,000 shares of the biotechnology company's stock worth $99,000 after acquiring an additional 3,000 shares during the last quarter. Finally, Mariner LLC increased its holdings in BioCryst Pharmaceuticals by 32.1% in the fourth quarter. Mariner LLC now owns 13,258 shares of the biotechnology company's stock valued at $100,000 after buying an additional 3,224 shares during the last quarter. Institutional investors and hedge funds own 85.88% of the company's stock.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.